Dr Marco Herold-Lab Team

Dr Marco Herold-Lab Team

In addition to our research on BCL-2 family proteins, my laboratory is responsible for setting up new genome editing technology within the Institute. This is being used for the production of new in vivo models as well as a whole genome screening platform.

Andrew Kueh, Postdoctoral Fellow, BSc(Hons) MB BS PhD Melbourne
Project: Development of CRISPR/Cas9 technology for generating mutant mice
Key publication: Kueh AJ, Herold MJ. Using CRISPR/Cas9 technology for manipulating cell death regulators. Methods Mol Biol. 2016 1419:253-64. PMID: 27108444

Martin Pal, Postdoctoral Fellow, PhD Cologne
Project: Development of CRISPR/Cas9 technology for generating mutant mice

Margs Brennan, PhD Student, BSc (Hons) Melbourne
Key publication: Lang MJ, Brennan MS, O'Reilly LA, Ottina E, Czabotar PE, Whitlock E, Fairlie WD, Tai L, Strasser A, Herold MJ. Characterisation of a novel A1-specific monoclonal antibody. Cell Death Dis. 2014 Dec 4; 5:e1553. PMID: 25476901

Erin Lawrence, PhD Student, BSc(Hons) Melbourne
Project: Investigating novel cancer driving genes and mutations in haematological malignancies

Ranja Salvamoser, PhD Student, MSc LMU Munich
Project: Analysing the impact of deleting CARD containing caspases on different forms of cell death

Robyn Schenk, PhD Student, BSc(Hons) Canterbury
Project: Determining the role of the pro-survival Bcl-2 family member A1 in lymphoma and leukaemia
Key Publication: Schenk RL, Tuzlak S, Carrington E, Zhan Y, Heinzel S, Teh CE, Gray DHD, Tai L, Lew A, Villunger A, Strasser A, Herold MJ. Characterisation of mice lacking all functional isoforms of the pro-survival BCL-2 family member A1 reveals minor defects in the haematopoietic compartment. Cell Death Differ. 2017 Mar;24(3):534-545. PMID: 28085150

Lin Tai, Research Assistant, BAppSc Swinburne MSc La Trobe

Super Content: 
Three researchers standing outside a building

Researchers have genetically engineered a laboratory model for testing the effectiveness of new anti-cancer drugs called MCL-1 inhibitors.